AN INTEGRATED HEART-ON-A-CHIP NAM RESOLVES DISTINCT CLINICAL PHENOTYPES OF MYOCARDIAL ISCHEMIA-REPERFUSION INJURY
Background: Reperfusion is required for myocardial salvage yet itself injures the heart, and cardioprotective interventions that reduce infarct size experimentally have repeatedly failed to improve outcomes in patients. These interventions are evaluated against viability or infarct size alone, whereas ischemia-reperfusion (I/R) injury produces structural, biochemical, and contractile dysfunction…
Background: Reperfusion is necessary for myocardial survival, but it simultaneously damages the heart. Attempts to develop cardiac-protective interventions that minimize infarct size have not led to improved patient outcomes because these trials only consider viability or infarct size. Myocardial ischemia-reperfusion (I/R) injury causes structural, biochemical, and contractile dysfunction within the same tissue. Previously, there was no in vitro methodology that addressed all three aspects simultaneously.
Methods: To address this limitation, a heart-on-a-chip platform was developed to culture neonatal rat ventricular myocytes (NRVMs) on muscular thin films. These cardiomyocytes were subjected to normoxia, 2 hours of ischemia, and then 2 hours of reperfusion. The changes in sarcomeric architecture, cardiomyocyte injury, cardiac troponin I release, and contractile stress were quantified and monitored using immunofluorescence, LIVE/DEAD staining, cardiac troponin I release into conditioned media, and beat frequency recordings, respectively.
Results: During ischemia, the z-line density decreased, while the architectural metrics remained stable, implying cell loss rather than sarcomere disorganization. Moreover, viability decreased, troponin levels increased, and all contractile stress components declined. However, the spontaneous beat frequency remained unchanged. Upon reperfusion, these uniform depressions were fractured; cell death and troponin release escalated further, but the structural integrity stayed unchanged from the ischemic state.
Thus, every functional alteration occurred in a depleted but architecturally intact cardiomyocyte population. Although systolic stress partially recovered, diastolic stress exceeded baseline, resulting in suppressed active stress despite oxygen recovery. Beat frequency increased significantly with pronounced variability.
Conclusions: The heart-on-a-chip NAM successfully resolved structural, biochemical, and contractile injury that global indices often combine. It distinguished the ischemic from the reperfusion pathophysiology. Remarkably, individual readouts corresponded to distinct clinical syndromes of ischemic injury, indicating the platform's potential for future testing of cardioprotective candidates against the full injury phenotype.
Rewritten by urgent.news; may contain errors — check the original.